Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF JULY 24, 2024 SAM #8275
SOURCES SOUGHT

66 -- Ambr 250 or Equal High Throughput Bioreactor System for NIAID VPP

Notice Date

7/22/2024 11:14:35 AM
 

Notice Type

Sources Sought
 

NAICS

334516 — Analytical Laboratory Instrument Manufacturing
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

SS-NIAID-24-2220774
 

Response Due

8/5/2024 12:00:00 PM
 

Archive Date

08/20/2024
 

Point of Contact

Kathy Song, Linda Smith
 

E-Mail Address

kathy.song@nih.gov, linda.smith2@nih.gov
(kathy.song@nih.gov, linda.smith2@nih.gov)
 

Description

Introduction This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources who could provide a brand name or equal to a Sartorius Ambr 250 high-throughput bioreactor systems as per FAR 52.211-6. Project Summary The National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC), Vaccine Production Program (VPP) is seeking to acquire two (2) Brand Name Sartorius Ambr 250 �high-throughput bioreactor systems for its Cell Culture Development (CCD) team for mammalian cell culture clone and growth condition screening processes.� The CCD team feeds into and generates work for the Downstream, Analytical, and Formulations departments of the VPP.� This acquisition ensures CCD has a suite of reliable small-scale bioreactors capable of broad screening that will prevent bottlenecks and delays to work. Specifically, NIAID, VRC, VPP is seeking two (2) high-throughput bioreactor systems that includes all components and services outlined in the attached Technical Specification Requirements Document. The high-throughput bioreactor systems must meet all the required minimum technical requirements listed below: Must be high throughput, 24-way, scale-down model designed for process development. Each unit must have a length no greater than 400 cm (13ft 2in) and a depth of not more than 115 cm (3ft 10 in), and a height not more than 249 cm (8 ft 2in) excluding space for PC, chiller, and other ancillary equipment. Works on available power, 3 phase (plus neutral and primary earth) 380-44 VAC (phase to phase, 50/60Hz and capable of a minimum of 15A per phase and have an electrical disconnect isolator. Both systems must possess the ability to be hardwired. Both Systems must include a chiller which operates on 230 V supply @50 Hz with rated load current of approximately 8.8 AMPs. Each system must have ability to support unlubricated oxygen, nitrogen, and carbon dioxide supplies between 1.5 to 2 bar (20-29 psi). Perfusion system must allow for up to 3.5 bar compressed air inlet to instrument via supplied 6mm OD polyurethane tubing. Stirred tank system must allow for up to 2 bar compressed air inlet to instrument via supplied 6mm OD polyurethan tubing. Working area is equivalent to a Class II Biosafety Cabinet (BSC) interior. Suitable for both perfusion and standard fed-batch cell culture processes. Should provide individual bioreactor control for DOE optimization. Capable of integrating automated sampling with at-line analysis options for pH, cell count, or metabolite analysis. Capable of inputting processes algorithms for Design of Experiments (DOE) protocols. Compatible with the following consumables: Single-Use Perfusion Bioreactor Vessels: Fully assembled, irradiated, and ready to use to minimize setup and turnaround time. Must include industry standard hollow fibre membranes (0.2 �m or 30 kDa, PES, Spectrum) for accurate large-scale process performance prediction. Single-use pressure sensors for monitoring transmembrane pressure (TMP). Perfusion Towers: Support and control perfusion pump chambers, pinch valve cassette, and perfusion filter. Flow Control and Collection System: Includes perfusion crossflow and permeate pumps. Automated bleed functions. Collection sets with bags and tubing management features for both permeate and bleed fluids. Walk-away permeate sampling system for samples up to 10 mL. Liquid Handling Unit: Facilitates addition of media, feed, cells, and reagents. Capable of sampling from bioreactor vessels using either 10 mL or 300 �L pipettes. Transfer samples to deck locations or integrated analyzers. Control Software: User interface optimized for protocol configuration, control, and visualization of multiple parallel bioreactors. Full control over individual bioreactors. High Productivity System: Automation must enable a single user to conduct multiple bioreactor experiments, including DOE. Single-use bioreactors must reduce operator time needed for cleaning and setup. Space and Facility Efficiency: Compact design with a minimal laboratory footprint. Single-use bioreactors must reduce the need for bioreactor wash-up and autoclaving. Supports automatic clean-in-place (CIP). Consistency and Reliability: Automated control and liquid addition to reduce variation and human error. Consistent data sets for better analysis and decision-making. Automated Sampling: Aseptic pipetting to reduce operator time significantly. Integration with at-line analyzers for pH, cell count, and metabolite analysis. (existing ViCell Blue and NovaFlex II instruments) SCADA integration: Must be able to be integrated into Program�s current system which is Lucullus. Anticipated Period of Performance It is anticipated that an award will be made on or about September 27, 2024. �Delivery of the bioreactor systems are required within 65 days upon award. Capability Statement/Information Sought If your organization has the potential capacity to provide high-throughput bioreactor systems which meet the minimum requirements and performance capabilities listed above, please provide the following information: Organization name, address, point of contact, email address, website address, telephone number, UEI number. Type of business (e.g., 8(a), HUBZone, Other than Small, etc.)� pursuant to the applicable NAICS code. Identification of any Best-In-Class contract vehicles including Government Wide Acquisition Contracts (GWAC) (e.g., GSA schedule) they may possess or are aware of that would support this possible requirement. If your organization does not provide the products/services under a GWAC, please identify availability as OPEN MARKET ONLY. Tailored capability statement addressing the capability of the bioreactor system to meet NIAID�s minimum requirements. Capability document shall be no more than six pages. Place of manufacture for the bioreactor systems and components. If this instrument is not manufactured in the United States, please state if the instrument is TAA compliant. Evidence that the organization is an authorized reseller or manufacturer of the high throughput bioreactor systems. Authorized resellers shall identify the OEM of the equipment proposed in their capability statement. Only OEM products are acceptable. Provide Information regarding sustainability sustainable of the equipment and any associated parts.� Are any parts of the system energy efficient consistent with ENERGY STAR certified or FEMP designated products.� Furthermore, are there any sustainability practices materials or practices such as use of recovered materials, biobased products, or alternative to ozone-depleting substances used in the manufacturing process of the bioreactor systems. Submission Instructions Interested businesses who consider themselves qualified to provide the above listed high throughput bioreactor systems are invited to submit a response to this Sources Sought Notice by August 5, 2024 at 3:00 PM EST. All responses under this Sources Sought Notice shall be emailed to Kathy Song at kathy.song@nih.gov. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/8ad4ca84034844c38fabb0cecefb1407/view)
 

Place of Performance

Address: Gaithersburg, MD 20878, USA

Zip Code: 20878

Country: USA
 

Record

SN07138470-F 20240724/240722230122 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |